The diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) and its precursor, metabolic dysfunction-associated steatotic liver disease (MASLD), continues to pose difficulties for clinicians. Symptoms are frequently absent or nonspecific, and until recently, liver biopsy remained the only definitive diagnostic method. This procedure carries risks, incurs high costs, and is not widely accessible. Now, a variety of noninvasive tests (NITs) are transforming clinical assessment, offering safer, faster alternatives that can be incorporated into regular patient care.
Noninvasive tests now lead MASLD diagnosis
Major medical societies, including the American Gastroenterological Association (AGA), the American Association for the Study of Liver Diseases (AASLD), and the European Association for the Study of the Liver (EASL), now recommend NITs as primary tools for evaluating MASLD and MASH. These tests—ranging from blood-based scores to advanced imaging—help identify patients at risk for advanced fibrosis, inform treatment decisions, and reduce the need for biopsies. The shift toward these methods reflects both technological progress and the recognition that early detection is essential. Delayed diagnosis increases the likelihood of cirrhosis, liver failure, and mortality.
The Fibrosis-4 Index (FIB-4) stands as the most commonly used NIT, calculated from age, platelet count, and liver enzyme levels. Guidelines designate it as the preferred first-line screening tool due to its accessibility, low cost, and ability to exclude advanced fibrosis in low-risk individuals. For patients with MASLD and type 2 diabetes, obesity combined with cardiometabolic risk factors, or persistently raised liver enzymes, a FIB-4 score below 1.3 (or 2.0 for those over 65) indicates a low risk of advanced fibrosis. Such patients can then be managed in primary care settings with follow-up testing every 1 to 3 years.
When FIB-4 results are abnormal or unclear, clinicians proceed to second-line tests. The Enhanced Liver Fibrosis (ELF) test, a proprietary blood assay measuring three fibrosis biomarkers, serves as one option. A score of 9.8 or higher signals an increased risk of cirrhosis and liver-related complications. However, ELF testing requires specialized kits and is less widely available than FIB-4, which relies on standard lab values already collected during routine care.
Imaging methods refine liver fat and fibrosis detection
For greater diagnostic certainty, imaging-based tests provide direct measurements of liver stiffness and fat content. Vibration-controlled transient elastography (VCTE), marketed as FibroScan, uses ultrasound to assess liver stiffness in kilopascals (kPa). It is widely adopted in primary care and non-hepatology settings, delivering rapid, point-of-care results. During the same examination, the controlled attenuation parameter (CAP) can estimate liver fat, though its precision lags behind MRI for long-term monitoring.
MRI-based methods, particularly MRI proton density fat fraction (MRI-PDFF), represent the gold standard for noninvasive liver fat quantification. This technique measures fat content across the entire liver with high accuracy, making it ideal for research and clinical settings requiring precision. For fibrosis staging, magnetic resonance elastography (MRE) combines MRI with mechanical wave imaging to produce stiffness maps, closely matching biopsy accuracy.
No single test offers perfect reliability. When clinical findings and NIT results conflict, clinicians often integrate multiple approaches—for example, pairing VCTE with the ELF score—to strengthen diagnostic confidence. The selection of a test depends on factors such as availability, cost, and patient risk profile. In high-risk cases, those involving multiple metabolic conditions, alcohol use, or a family history of MASH-related cirrhosis, doctors may prefer MRE over VCTE, even if initial VCTE results suggest low fibrosis risk. Conversely, if VCTE indicates moderate-to-advanced fibrosis in a low-risk patient, MRE can provide confirmation.
Accessibility remains a significant hurdle. While FIB-4 and VCTE are becoming more widely available, advanced tests like MRE and ELF are not universally offered. Clinicians must balance test performance with practical limitations, ensuring results are interpreted within the broader clinical context. The objective, as one specialist noted, is to use these tools as supplements to clinical judgment, rather than replacements for it.
The development of NITs aligns with broader trends in medicine, emphasizing precision, accessibility, and reduced invasiveness. For MASLD and MASH, where early intervention can prevent permanent liver damage, these tests represent a critical advancement. However, their success depends on one factor above all: widespread adoption. As guidelines become more established and costs decrease, the focus will shift from proving their effectiveness to ensuring consistent use in the clinics where patients require them most.
While the diagnostic process continues to evolve, the next major challenge is ensuring that existing tests reach those who need them, and that upcoming NITs, still under development, provide even clearer diagnostic answers.
Balancing test accuracy with real-world clinic limits
Test selection depends not only on diagnostic performance but also on what is realistically feasible in a given practice. Although MRE and MRI-PDFF offer the highest accuracy for fibrosis staging and fat measurement, their use is often restricted by cost, equipment availability, and patient factors such as obesity or claustrophobia. VCTE, by contrast, is more commonly used in primary care and non-specialist settings, where its portability and speed make it a practical second-line option after FIB-4. Clinicians frequently turn to VCTE when imaging is necessary but advanced MRI is unavailable, particularly in regions lacking hepatology expertise.
For patients with conflicting results, such as a high FIB-4 score but low VCTE stiffness measurements, experts recommend combining multiple tests to clarify risk. For instance, if VCTE suggests low fibrosis but clinical indicators (e.g., persistent metabolic dysfunction or raised ALT/AST) raise concerns, an ELF test or MRE may be necessary. Specialists emphasize that no single test should determine treatment; instead, results must be evaluated alongside a patient’s full clinical history, including metabolic comorbidities, alcohol consumption, and family risk factors. This layered approach ensures that high-risk individuals are not overlooked while avoiding unnecessary procedures in low-risk cases.
Understanding of MASLD and MASH remains limited due to insufficient awareness among both clinicians and patients. Many primary care providers are unfamiliar with updated guidelines or the complexities of test selection, leading to missed opportunities for early detection. The AGA and AASLD have highlighted the need for educational initiatives targeting frontline practitioners, particularly in endocrinology, cardiology, and primary care, where MASLD often first appears. Meanwhile, patients, especially those with obesity, type 2 diabetes, or metabolic syndrome, may disregard symptoms like fatigue or mild abdominal discomfort, delaying medical evaluation.
Regional gaps and workflow hurdles persist
Availability of these tests also varies significantly by region. Urban medical centers and large hospitals often have access to MRE and ELF testing, while rural clinics may rely solely on FIB-4 or VCTE, limiting their ability to assess risk accurately. Even in well-equipped settings, test utilization depends on workflow integration. VCTE can be performed in under five minutes during a routine visit, whereas MRE requires scheduling in radiology departments, which may not accommodate urgent referrals. This variation shows the need for standardized protocols that match test selection with local resources and patient needs.
Emerging NITs, including new blood-based biomarkers and AI-driven predictive models, show promise for further improving accessibility. For now, the most urgent priority is ensuring that current tools are consistently applied in clinics where MASLD and MASH are most prevalent. The aim is not merely to replace biopsies but to integrate these tests into standard care pathways, shortening the gap between symptom onset and accurate diagnosis.
Dr. Na Li stresses that no single test should dictate patient management. Instead, results must be interpreted within the context of a patient’s complete clinical picture, including metabolic risk factors, alcohol history, and family medical background. This wide-ranging approach reduces the risk of missing high-risk individuals while avoiding unnecessary interventions in low-risk cases.
Dr. Adam Myer highlights that even in well-resourced settings, test adoption depends on how well they fit into existing workflows. For example, VCTE can be seamlessly incorporated into routine visits, whereas MRE requires coordination with radiology departments, which may not always align with urgent care needs. This discrepancy emphasizes the importance of tailored protocols that account for local capabilities and patient requirements.